AXSM vs. CORT, HRMY, TARO, XNCR, VIR, INVA, TXG, RARE, CRNX, and SWTX
Should you be buying Axsome Therapeutics stock or one of its competitors? The main competitors of Axsome Therapeutics include Corcept Therapeutics (CORT), Harmony Biosciences (HRMY), Taro Pharmaceutical Industries (TARO), Xencor (XNCR), Vir Biotechnology (VIR), Innoviva (INVA), 10x Genomics (TXG), Ultragenyx Pharmaceutical (RARE), Crinetics Pharmaceuticals (CRNX), and SpringWorks Therapeutics (SWTX). These companies are all part of the "medical" sector.
Axsome Therapeutics (NASDAQ:AXSM) and Corcept Therapeutics (NASDAQ:CORT) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, community ranking, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.
Axsome Therapeutics presently has a consensus price target of $121.92, indicating a potential upside of 65.67%. Corcept Therapeutics has a consensus price target of $40.10, indicating a potential upside of 46.73%. Given Axsome Therapeutics' higher possible upside, analysts plainly believe Axsome Therapeutics is more favorable than Corcept Therapeutics.
In the previous week, Axsome Therapeutics had 28 more articles in the media than Corcept Therapeutics. MarketBeat recorded 46 mentions for Axsome Therapeutics and 18 mentions for Corcept Therapeutics. Corcept Therapeutics' average media sentiment score of 0.46 beat Axsome Therapeutics' score of 0.22 indicating that Corcept Therapeutics is being referred to more favorably in the news media.
Corcept Therapeutics received 101 more outperform votes than Axsome Therapeutics when rated by MarketBeat users. Likewise, 70.62% of users gave Corcept Therapeutics an outperform vote while only 68.67% of users gave Axsome Therapeutics an outperform vote.
Axsome Therapeutics has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Comparatively, Corcept Therapeutics has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500.
81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are owned by institutional investors. 24.5% of Axsome Therapeutics shares are owned by company insiders. Comparatively, 20.5% of Corcept Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Corcept Therapeutics has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.
Corcept Therapeutics has a net margin of 22.38% compared to Axsome Therapeutics' net margin of -88.41%. Corcept Therapeutics' return on equity of 24.19% beat Axsome Therapeutics' return on equity.
Summary
Corcept Therapeutics beats Axsome Therapeutics on 12 of the 18 factors compared between the two stocks.
Get Axsome Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AXSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Axsome Therapeutics Competitors List
Related Companies and Tools
